You are here

Two Formulations of Promethazine Suppositories Approved by the FDA

SOUTH PLAINFIELD, N.J. (Dow Jones)--Able Laboratories Inc. received Food and Drug Administration (News - Websites) approval for its abbreviated new drug application for two additional formulations of promethazine suppositories.

The product, which is used to treat allergies, anaphylactic reaction, pre- and post-operative sedation and nausea and vomiting, is a generic equivalent to Wyeth's (WYE) Phenergan suppositories.

In a press release Monday, pharmaceutical maker Able Laboratories said it now offers generic versions of Phenergan suppositories in 50 milligrams, 25 mg and strengths.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks